Subscribe
shutterstock_1123492958_willy_barton
Willy Barton / Shutterstock.com
14 April 2020Big Pharma

Sanofi and GSK launch coronavirus vaccine collaboration

Sanofi and  GlaxoSmithKline (GSK) are pooling resources to create a vaccine for COVID-19, in what they call an “unprecedented” collaboration between the two pharma companies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.
Big Pharma
Sanofi under fire over priority US access to COVID-19 vaccine
15 May 2020   Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.
Big Pharma
Sanofi under fire over priority US access to COVID-19 vaccine
15 May 2020   Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

More on this story

Americas
GSK claims Amgen v Sanofi decision “threatens” innovation
29 April 2021   GlaxoSmithKline has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”
Big Pharma
Fed Circuit refuses Amgen unit appeal in win for Sanofi
15 October 2020   The US Court of Appeals for the Federal Circuit has dismissed Immunex’s appeal against a decision invalidating its patent on treating inflammatory disorders.
Big Pharma
Sanofi under fire over priority US access to COVID-19 vaccine
15 May 2020   Sanofi is facing criticism after CEO Paul Hudson said the US was likely to have priority access on any COVID-19 vaccine produced by the French pharmaceutical company.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB